悦康药业集团股份有限公司 2024 年年度股东大会会议资料 悦康药业集团股份有限公司 会议资料 悦康药业集团股份有限公司 2024 年 年度股东大会会议资料 悦康药业集团股份有限公司 2024 年年度股东大会会议资料 目 录 悦康药业集团股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会 规则》以及《悦康药业集团股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，认真做好召开股东大会的各项工作，特制定本须知： 九、本公司不向参加股东大会的股东发放礼品，不负责安排参加股东大会股 东的住宿等事项，以平等对待所有股东。 悦康药业集团股份有限公司 一、为保证股东大会的严肃性和正常秩序，切实维护股东的合法权益，除出 席会议的股东及股东代表、董事、监事、公司高级管理人员、公司聘任律师及中 介机构外，公司有权依法拒绝其他人员入场。 二、请出席会议的股东及股东代表在会议召开前 20 分钟到达会议现场办理 签到手续。大会工作人员将对出席会议者的身 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4]. Core Insights - The company achieved a revenue of 27.98 billion RMB in 2024, representing a year-on-year growth of 22.63%. The net profit attributable to shareholders was 6.34 billion RMB, up 47.28% year-on-year [1]. - The innovative drug revenue grew rapidly, reaching 13.89 billion RMB in 2024, a 30.6% increase year-on-year. The company has received approvals for 17 new molecular entity drugs in China and has made significant progress in overseas licensing [2]. - The company is enhancing its technology platforms, including PROTAC, peptides, monoclonal antibodies, and ADCs, with 26 self-developed innovative molecules entering clinical stages [3]. - Revenue projections for 2025, 2026, and 2027 are estimated at 30.84 billion RMB, 34.87 billion RMB, and 39.75 billion RMB, respectively, with expected growth rates of 10.22%, 13.04%, and 14.00% [4]. Summary by Sections Performance Review - In 2024, the company reported a revenue of 27.98 billion RMB, a 22.63% increase from the previous year, and a net profit of 6.34 billion RMB, reflecting a 47.28% growth [1]. Operational Analysis - The innovative drug segment saw a revenue of 13.89 billion RMB, with a 30.6% year-on-year increase. The company has successfully launched 17 new drugs in China and made strides in international licensing agreements [2]. - The company is developing various technology platforms and has 26 innovative molecules in clinical trials, with significant advancements in ADC products [3]. Profit Forecast and Valuation - The company is projected to achieve revenues of 30.84 billion RMB, 34.87 billion RMB, and 39.75 billion RMB in 2025, 2026, and 2027, respectively, with corresponding net profits of 6.95 billion RMB, 7.71 billion RMB, and 8.93 billion RMB [4].

● 本报记者李梦扬 3月25日晚间，复星医药（600196）发布2024年报。2024年，复星医药实现营业收入410.67亿元，同比 微降0.8%；归母净利润27.70亿元，同比增长16.08%；经营现金流净额44.77亿元，同比增长31.13%。在 近日复星医药2024年年报媒体沟通会上，复星医药董事长吴以芳在接受中国证券报记者采访时表示， 2024年，复星医药进一步聚焦创新药和高值器械业务发展，推进产品结构和策略转型。未来也将继续坚 持创新驱动与全球化发展，积极拥抱AI，集中资源聚焦核心业务，持续推进精益管理与运营效率的提 升，与中国生物医药产业同频共振，迈向高质量发展新阶段。 持续推进创新转型 3月25日晚间，复星医药发布2024年报。2024年，复星医药实现营业收入410.67亿元，同比微降0.8%； 归母净利润27.70亿元，同比增长16.08%；经营活动产生的现金流量净额44.77亿元，同比增长31.13%。 资产结构方面，吴以芳表示，公司2024年持续推进资产结构优化，通过出售资产总体回笼资金近30亿 元。2025年，公司将继续加大回笼资金力度，退出和整合非核心、非战略、低效率的资产，集中资源聚 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 二零二五年三月二十六日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本公司的非執行 董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先生 ; 而本公司的獨立非執行 董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗婕女士。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有限公司 2024 年年度報告摘要》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 劉寧 中國，珠海 * 僅供識別 1 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-018 丽珠医药集团股份有限公司 2 ...

Core Viewpoint - The report highlights the significant advancements and strategic initiatives of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in the pharmaceutical and medical device sectors, emphasizing innovation, compliance, and market expansion as key drivers for growth in 2024. Company Overview - The pharmaceutical industry is driven by innovation, with the government prioritizing the development of innovative drugs as a new emerging industry [5][6] - The company has maintained a strong position in the industry, ranking 4th in the "2023 Annual Top 100 Chinese Pharmaceutical Industry" list [12] Industry Development Status - The implementation of the "Drug Standard Management Measures" in January 2024 aims to enhance drug quality and safety [8] - Continuous anti-corruption efforts in the medical and pharmaceutical sectors are expected to promote long-term healthy development [8] - The government has introduced policies to support the upgrade of medical equipment, providing new sales opportunities for the medical device industry [9] Business Highlights - The company achieved operating revenue of 41.067 billion yuan in the reporting period, with significant growth in innovative products [26] - The net profit attributable to shareholders increased by 16.08% to 2.770 billion yuan, with a net profit excluding non-recurring gains and losses rising by 15.10% [26] - The company has focused on innovation, with R&D investment totaling 5.554 billion yuan, of which 3.644 billion yuan was dedicated to R&D expenses [27] Product Development - The company has received approvals for 16 indications across 7 innovative drugs and biosimilars during the reporting period [28] - The innovative PD-1 monoclonal antibody, Hanshu (SruLi), received approval for a new indication in China [29] - The company has successfully launched several products in international markets, including the biosimilar trastuzumab in the US and Canada [29][30] Global Expansion - The company has established a strong global presence, with a commercial team of over 1,000 people covering markets in the US, Africa, and other regions [42] - The company has formed strategic partnerships to enhance its international market access and product commercialization [38][39] Compliance and Regulatory Environment - The company is committed to adhering to regulatory requirements and enhancing compliance in response to the ongoing anti-corruption initiatives in the pharmaceutical industry [25] - The company has implemented measures to ensure the quality and safety of its products, aligning with national standards and regulations [41]

战略性专注于感染、慢病及肿瘤等治疗领域。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，广东东阳光药业股份有限公司（以下简称"东阳光药"）于2024年12月11日正式 向港交所递交招股说明书，计划以介绍方式在港上市，中金公司担任独家保荐人。 成立于2003年的东阳光药作为一家综合性制药公司，专注于创新药，亦涉及改良型新药、仿制药和 生物类似药，战略性专注于感染、慢病及肿瘤等治疗领域。根据弗若斯特沙利文报告， 按2018年至 2023年中国医药产品的销售收入统计，这三大治疗领域最具市场潜力，并有重大未满足的医疗需 求。 截至2024年6月30日，东阳光药在全球(包括中国、美国及欧洲)拥有147款获批药物，还有超过100 款在研药物，包括45款1类在研创新药物，其中三款获NMPA就于中国上市审评的创新药物及十款在 研创新药物处于II期或III期临床试验。 同时，东阳光药也是凭借自主研发成功实现一款1类创新药上 市，三款1类创新药申请上市的少数中国制药公司之一。此外，东阳光药致力于将AI技术应用于药物 研发的各个阶段，并已建立多个先进的AI驱动模型以提升 ...